Glycovax Pharma Inc. is starting the large-scale production of a new glycolipidic vaccine adjuvant developed by the National Research Council of Canada (NRC). The NRC license has allowed Glycovax to optimize SLA manufacturing by developing a fully synthetic process meeting Good Manufacturing Practices (GMP).
Posted in News